

ACM BIOLABS ANNOUNCES VETERINARY VACCINE SUBSIDIARY, FUNDING & LICENSING

Singapore, 15th January 2018 – ACM Biolabs Pte Ltd announced today that it has set up subsidiary, AAVACC Pte Ltd (“**AAVACC**”), secured funding and signed key license agreements for AAVACC’s development.

Dr. Peter Moran, COO of ACM Biolabs, said “We are very pleased to announce that we have incorporated AAVACC Pte Ltd in Singapore as a subsidiary of ACM Biolabs Pte Ltd. AAVACC is specifically focused on bringing veterinary vaccines to market based on the ACM technology platform. In addition, we have raised sufficient funding, by way of a direct equity investment into AAVACC, such that it may continue progressing our lead veterinary vaccines through regulatory approvals and into production. Last, but not least, we have signed technology licensing agreements between AAVACC, ACM Biolabs, ETPL¹ and NTUitive¹ such that AAVACC has the exclusive rights to develop and market veterinary vaccines based on ACM technology.”

1. Both as defined below.

About ACM Biolabs Pte Ltd

ACM Biolabs is a synthetic biology company using its proprietary Artificial Cell Membrane (“**ACM**”) technology platform to allow its customers to develop diagnostics, therapeutics and vaccines targeting novel membrane proteins. ACM technology is being used by the world’s leading pharmaceutical companies to develop products requiring membrane proteins that are difficult or impossible to work with using traditional methods. ACM Biolabs has licensed technology from both A*STAR and NTUitive.

About ETPL

ETPL is the commercialisation arm of the Agency for Science, Technology and Research (A*STAR), Singapore’s lead agency for fostering world-class scientific research and talent. As a one-stop resource, ETPL supports A*STAR in transforming the economy through driving innovation and commercialising its research outcomes. ETPL enhances the research output of A*STAR scientists by translating their inventions and intellectual capital into marketable products, processes and services. Through shaping and facilitating licensing deals and spin-offs, ETPL actively engages industry leaders and players to commercialise A*STAR’s technologies and apply them to building ecosystems that benefit business, industry and economy.

About NTUitive

Nanyang Technological University (“**NTU**”) – NTUitive Pte Ltd (“**NTUitive**”) is the Nanyang Technological University’s innovation and enterprise company. NTUitive is responsible for the Innovation and Enterprise agenda at NTU. In addition to building an ecosystem that fosters entrepreneurship among its faculty, students, and alumni, NTUitive develops, manages, and commercialises the intellectual property assets of the University. NTUitive sees these roles as mutually complementary and synergistic. Ultimately, its activities are intended to translate knowledge into tangible socioeconomic benefit. NTU is a research-intensive University which is consistently ranked among the world’s best Universities.

Media Contact: info@ACMBiolabs.com